Synta Pharmaceuticals SNTA today announced results from
an interim analysis of the Phase 2b portion of the GALAXY trial, a
global, randomized, multi-center Phase 2b/3 study designed to evaluate
the efficacy and safety of the Company's lead Hsp90 inhibitor,
ganetespib, as second-line treatment for advanced non-small cell lung
cancer (NSCLC). The results showed good tolerability for the combination
of ganetespib (G) and docetaxel (D), as well as meaningful improvements
in overall survival (OS) in adenocarcinoma patients receiving docetaxel
plus ganetespib compared to those receiving docetaxel alone. The results
were presented by Suresh Ramalingam, MD, Professor, Hematology & Medical
Oncology, and Director, Translational Thoracic Malignancies Program, of
the Winship Cancer Institute of Emory University, in a poster session at
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in